PC Biomaterials offer the following properties:
FDA-cleared claim (click for FDA .pdf): "....PC coating aids in the prevention of thrombus formation on the guidewire tip during short-term clinical usage...."
- Resistant to Bacterial Adhesion and Biofilm Formation
FDA-cleared claim (click for FDA .pdf): "....The coating has been shown to be resistant to staphylococcal biofilm formation and pseudomonal biofilm formation...."
- Wettable and Dehydration Resistant
FDA-cleared claim (click for FDA .pdf): "....may provide improved comfort for contact lens wearers who experience mild discomfort or symptoms relating to dryness during lens wear...."
The following table summarises how the features of PC materials translate into expected benefits for devices incorporating them:
| PC Technology Feature |
Expected Clinical Benefit |
| Reduced protein adhesion/activation | Increased biocompatibility |
| Reduced blood activation | Reduced risk of thrombus |
| Reduced bacterial adhesion | Reduced risk of infection |
| Reduced inflammatory response | Reduced risk of fibrosis/rejection
Increased patient comfort |
| Hydrophilic/lubricious coatings | Improved comfort, ease of use |
| Durable | Prolonged device effectiveness |
| Non-toxic and bio-inert | Rapid regulatory approval |
| Drug delivery | Step change in device performance |
Many of these benefits have been established in the clinic and there are
numerous reports detailing the results from in vitro studies, some of which are shown below. Furthermore, PC polymers have been found to be excellent drug delivery platforms for a broad range of actives. It is widely recognised that drug delivery is proving to be a step-change in the medical device area as passive devices become active devices through release of therapeutic agents such as anti-inflammatories, analgesics, anti-microbials etc. PC Biomaterials offer combined benefits of enhanced biocompatibility with controlled drug-delivery capability.
 
 
| 
